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Abstract
With the advent of whole-genome and whole-exome sequencing, high-quality catalogs of recurrently mutated cancer
genes are becoming available for many cancer types. Increasing access to sequencing technology, including bench-top
sequencers, provide the opportunity to re-sequence a limited set of cancer genes across a patient cohort with limited
processing time. Here, we re-sequenced a set of cancer genes in T-cell acute lymphoblastic leukemia (T-ALL) using
Nimblegen sequence capture coupled with Roche/454 technology. First, we investigated how a maximal sensitivity and
specificity of mutation detection can be achieved through a benchmark study. We tested nine combinations of different
mapping and variant-calling methods, varied the variant calling parameters, and compared the predicted mutations with a
large independent validation set obtained by capillary re-sequencing. We found that the combination of two mapping
algorithms, namely BWA-SW and SSAHA2, coupled with the variant calling algorithm Atlas-SNP2 yields the highest sensitivity
(95%) and the highest specificity (93%). Next, we applied this analysis pipeline to identify mutations in a set of 58 cancer
genes, in a panel of 18 T-ALL cell lines and 15 T-ALL patient samples. We confirmed mutations in known T-ALL drivers,
including PHF6, NF1, FBXW7, NOTCH1, KRAS, NRAS, PIK3CA, and PTEN. Interestingly, we also found mutations in several
cancer genes that had not been linked to T-ALL before, including JAK3. Finally, we re-sequenced a small set of 39 candidate
genes and identified recurrent mutations in TET1, SPRY3 and SPRY4. In conclusion, we established an optimized analysis
pipeline for Roche/454 data that can be applied to accurately detect gene mutations in cancer, which led to the
identification of several new candidate T-ALL driver mutations.
Citation: Kalender Atak Z, De Keersmaecker K, Gianfelici V, Geerdens E, Vandepoel R, et al. (2012) High Accuracy Mutation Detection in Leukemia on a Selected
Panel of Cancer Genes. PLoS ONE 7(6): e38463. doi:10.1371/journal.pone.0038463
Editor: Jo ¨rg D. Hoheisel, Deutsches Krebsforschungszentrum, Germany
Received December 28, 2011; Accepted May 5, 2012; Published June 4, 2012
Copyright:  2012 Kalender Atak et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Belgian federal government (Cancer Plan – Translational Research), the K. U. Leuven (grant GOA/11/010 to J. Cools and
PV; grant PF/10/016 SymBioSys to J. Cools and SA), the Foundation Against Cancer (grant 2010-154 to SA), the FWO-Vlaanderen (G.0287.07, J. Cools), and the
European Research Council (ERC-starting grant to J. Cools). KDK is a postdoctoral researcher funded by the FWO-Vlaanderen, PV is a Senior Clinical Investigator
supported by FWO-Vlaanderen, DP and MP are funded by Agentschap voor Innovatie door Wetenschap en Technologie. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The affiliation of WDG and HQ to Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH does not alter the authors’
adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: stein.aerts@med.kuleuven.be (SA); jan.cools@cme.vib-kuleuven.be (J. Cools)
. These authors contributed equally to this work.
Introduction
Next generation sequencing (NGS) technologies have signifi-
cantly improved our sequencing capacity in the past five years.
They are now widely used for research purposes and are starting
to find their way into clinical applications. Although whole
genome and whole exome sequencing approaches are successfully
implemented for mapping the genomic landscapes of many
human diseases, they are not routine strategies for detecting
molecular aberrations due to high costs, and long turnover times
(run and analysis times). Targeted re-sequencing, on the other
hand, is appealing in a clinical setting, given the lower sequencing
costs, shorter sequencing time and simpler data analysis.
Moreover, as the discovery of novel cancer genes by whole-exome
sequencing will gradually saturate and converge into a set of
commonly mutated genes in a particular cancer, the identification
of these mutations can yield important diagnostic and prognostic
information.
Despite the requirement of several days for library preparation
and target enrichment for all these platforms, the Roche/454
technology offers the advantages of short run times and data
analysis time. In addition, the more restricted data output is also
beneficial for turnaround time because fewer patient samples need
to be collected to fill an entire sequencing run. Based on these
advantages of the 454 platform for sequencing relatively small
gene sets, we invested in optimizing bioinformatics pipelines for
read mapping and variant calling of 454 reads, with the aim for
applying this both for research as well as for clinical purposes. We
focused on T cell acute lymphoblastic leukemia (T-ALL), an
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tion of developing T-cells [1]. A set of 97 genes was selected for
targeted sequencing. The set consisted of 58 cancer genes [2] and
39 candidate genes including tyrosine kinase and phosphotase
coding genes, chromatin modifiers, and several genes belonging to
the families of known cancer driver genes such as TET1-TET3, or
PIK3CB-PIK3CD-PIK3CG.
For accurate variant detection, we investigated several existing
analysis pipelines and compared their performance. Although the
companion software gsMapper is widely used in the analysis of 454
data [3], [4], [5], various alternative mapping and variant calling
algorithms have been developed, such as BWA-SW [6] and
SSAHA2 [7], BLAT [8] for mapping, and SAMTools [9],
VarScan [10], and Atlas-SNP2 [11] for variant calling. Li et al
[6] reviewed the long read aligners, and Shen et al [11] reviewed
the variant callers, however, to our knowledge, no comparison has
been performed on the combination of mapping and variant
calling algorithms in the context of mutation discovery.
Here, we analyzed and compared nine different combinations
of a mapping and variant calling algorithms and particularly
investigated to what extent low coverage positions can be included
in the variation calling process to increase the sensitivity of
mutation detection. Next, we apply the optimized pipeline to
identify mutations in a set of 58 cancer genes and 39 candidate
genes, across 18 T-ALL cell lines and 15 T-ALL patient samples,
and identify recurrent mutations in both known and novel drivers.
Results
Comparison of Mapping and Variation Calling Methods
for Roche/454 Data
The Roche companion software gsMapper is mostly used for the
analysis of Roche/454 data. This software first aligns the reads to
the reference genome and then lists all positions that are different
from the reference genome (variant calling). Although gsMapper
performed well in several studies [3], [4], [5], we wanted to assess
its performance on our data set and investigate whether we could
achieve better precision and accuracy using alternative aligners
and variant callers. We tested eight different combinations of a
long read aligner (BWA-SW, SSAHA2, BLAT) and a variant
caller (SAMTools, VarScan, Atlas-SNP2) and compared their
performance with gsMapper.
Each pipeline was applied to the reads obtained from seven T-
ALL cell lines and the performance of each pipeline was evaluated
by Sanger re-sequencing of 210 candidate variants that were
randomly taken from all predicted 8020 variants (containing both
SNPs and mutations) from all pipelines. As a measure of the
performance of each pipeline, we calculated the Matthews
correlation coefficient (MCC), which is a measure of prediction
accuracy that is calculated based on the number of successfully
predicted true positives and true negatives found by Sanger
sequencing (see Materials and Methods). When using default
parameter settings (Table S1), the performance of the different
pipelines was comparable, with an average MCC of 0.62, with no
alternative pipeline performing better than gsMapper (MCC of
0.82) (Table S1).
In NGS studies, the presence of duplicate reads (caused by a
PCR amplification step during library preparation) is a potential
source of false positive single nucleotide variant (SNV) prediction
[12]. Therefore, we added an additional step to remove duplicate
reads using Picard, resulting in a 2–24% increase in MCC,
depending on the pipeline, with an average MCC of 0.73 (Table
S1). This showed that duplicate removal is an important step for
obtaining correct variant calls.
Next, we further optimized the performance of each pipeline by
varying the minimal required number of reads (depth of coverage,
DoC) and the minimal required variant reads (variant allele
frequency, VAF). Changes in DoC thresholds mainly affected the
sensitivity, while varying VAF thresholds affected the predictions
in terms of specificity (Figure 1.A, Table S2). All the pipelines
reached their best performance with a DoC threshold of 3, and
with a minimum VAF threshold of 0.20 (when applicable) (Table
S1-S2). In a final effort to minimize false positive predictions, we
combined the two best mapping algorithms in one pipeline, which
further increased the sensitivity to 95% and the specificity to 93%.
The reason for this increase in accuracy is that certain predicted
variants that are caused by erroneous mapping (Figure S1) are
now filtered out. Although this final pipeline (SSAHA2+ BWA-SW
+ Atlas-SNP2) performs better than gsMapper (91.2% sensitivity
and 90.8% specificity), the difference is not large and gsMapper can
be considered as a valid (and often easy to use) alternative
(Figure 1.B).
Widespread Mutations in Cancer Genes Across 18 T-ALL
Cell Lines and 15 T-ALL Patient Samples
We applied the optimized pipeline determined above, consisting
of the SSAHA2+BWA-SW combination for read mapping, and
Atlas-SNP2 for variation calling, to identify mutations in a panel of
58 ‘‘cancer genes’’ across 18 T-ALL cell lines and 15 primary T-
ALL patient samples. This set of genes consists of 13 T-ALL
drivers (Figure 2.A.I) and 45 other genes involved in a variety of
cancers (Figure 2.A.II). All of these genes are present in the
Census [2] database of cancer genes except for the recently
discovered cancer genes ATOH1 and PHF6 [13], [14]. Since
PHF6 mutations are involved in T-ALL we added PHF6 to our list
of T-ALL drivers.
Sequence reads were mapped to the entire reference genome
and those reads that map to the selected genes were retained. This
resulted in 36% of reads that map to the target sequences on
average, with an average coverage of 24.2X and 16.3X for cell
lines and patient samples, respectively. Analysis of the sequence
data revealed that exons with a very low coverage had a
significantly higher GC-content compared to exons with higher
coverage (p-value 2.2e-16), a finding consistent with a previously
published study [15] (Figure S2). Of the 1565 exons targeted in
this study, 18 exons had no coverage in the cell lines or in the
patient samples (corresponding to 8710 bps); and 15 exons had no
coverage in the patient samples only (corresponding to 5197 bps).
On average, 94% and 86% of the targeted exons reached a mean
coverage equal or above 3 for the cell lines and the patient
samples, respectively.
Variation calling resulted in 836 distinct single nucleotide
variants (SNVs) in known cancer genes across the 33 samples. Cell
lines had significantly more SNVs in cancer genes than patient
samples (p-value ,0.001); on average 153 SNVs were detected per
cell line and 117 per patient sample. 56% of the predicted SNVs
were reported in dbSNP (http://www.ncbi.nlm.nih.gov/projects/
SNP/) or in the 1000 Genomes project (http://www.
1000genomes.org/) and were excluded from further analysis,
while the remaining 368 SNVs (Table S3) affected 55 of the 58
sequenced cancer genes, primarily in the exons (58.4%) and in
untranslated regions (23.9%). Furthermore, there were 8 SNVs
affecting splice sites. Of the exonic SNVs, 14 result in the gain of a
stop codon (called ‘‘stop gain’’ SNVs), 140 are non-synonymous
and the remaining 61 are synonymous coding variations.
To validate the mutations found in cell lines, we compared our
results with mutations determined by the Cancer Cell Line project
[16], which contains eleven of our 18 cell lines. Of the 35
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(determined by capillary sequencing) in the genes that are included
in our panel, 31 were recovered by the automated re-sequencing
on Roche/454 using the SSAHA2+ BWA-SW + Atlas-SNP2
analysis pipeline, corresponding to a recovery rate of 88.5%
(Table S4). Note that gsMapper recovered 30 mutations out of
35, resulting in a recovery rate of 85.7%. The mutations that were
missed by Roche/454 sequencing are either due to low coverage
at those positions (in two of the four missed mutations, both in
NOTCH1), or to low variant quality (one TP53 mutation), or to
sequencing errors (one NOTCH1 mutation is covered by 10 reads,
none of which contains the variant allele reported by the Cancer
Cell line project). With regards to specificity, both pipelines
performed well, for example on the FBXW7 gene for which we
find a protein altering point mutation in exactly the same five cell
lines as the Cancer Cell line project (out of the eleven common cell
lines). In conclusion, the automated re-sequencing using Roche/
454, with either the gsMapper pipeline or the SSAHA2+ BWA-
SW + Atlas-SNP2 pipeline, is to a very large extent in agreement
with mutations found by capillary sequencing.
Thirteen of the 58 cancer genes have been linked specifically to
T-ALL, and we identified protein altering mutations in at least one
of these genes in all cell lines and in 10 patient samples
(Figure 2.A.I). Of the other 45 cancer genes, 36 genes were
mutated (Figure 2.A.II), of which 25 were mutated in at least two
samples (cell line or patient). The genes with most mutations in T-
ALL cell lines are NOTCH1 (non-synonymous mutation in 9/18
cell lines), TP53 (10/18), FBXW7 (7/18), and NRAS (5/18).
These also have mutations in patient samples, except TP53,
suggesting that it may be easier to obtain cell lines from samples
with TP53 mutation or that TP53 mutations are acquired during
cell culture [17].
Identification of Recurrent JAK3 Mutations in T-ALL
We next determined if mutations in cancer genes could be
identified that were previously not linked to T-ALL. We found
several such mutations in T-ALL cell lines (Figure 2.A.II), but
their absence in the patient samples questions their relevance for
the pathogenesis of T-ALL.
Figure 1. Performance comparison and parameter optimization. (A) Different pipelines show different sensitivity and specificity. Varying DoC
and VAF thresholds in the variant calling process has an additional affect on the predictions in terms of sensitivity and specificity, respectively. Each
pipeline is represented with a different symbol and the performance of each pipeline (in terms of sensitivity and specificity) is plotted under varying
DoC and VAF thresholds. Note that the X-axis represents the false positive rate (1-specificity). In this ROC plot, the closer the point to the upper left
point of the graph, the better the sensitivity and the specificity. Different colors of the symbols indicate the performance of the pipeline under
changing VAF thresholds, and the two shaded boxes indicate the performance under changing DoC thresholds. The plot shows that (i) decreasing
the DoC threshold increases the sensitivity of all pipelines as indicated with the blue dotted line; (ii) increasing the VAF threshold increases the
specificity with a slight decrease in sensitivity as indicated (in the example of BLAT+VarScan pipeline) with the red dotted line; (iii) the BWA-
SW+SSAHA2+Atlas-SNP2 pipeline has the best performance among all pipelines under DoC=3 & VAF=0.20 thresholds as indicated with the yellow
arrow. The Roche pipeline is indicated with a black diamond shape since no parameter changes were performed on it, and SSAHA2+SAMTools and
BWA-SW+SAMTools pipelines were colored grey since no VAF threshold changes were performed on them. (B) The Matthews correlation coefficient
for each pipeline is shown for the most optimal performance of that pipeline (Table S1). It is interesting to note that the optimal performance of all
the pipelines, except Roche gsMapper, was observed for a DoC threshold of 3.
doi:10.1371/journal.pone.0038463.g001
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lines and patient samples. All JAK kinases, except TYK2 (see
below), are known oncogenes in leukemia and activating
mutations and translocations affecting JAK1, JAK2 and JAK3
were described in multiple, mainly myeloid, hematologic malig-
nancies [18]. Until recently, JAK1 was the only JAK family
member in which point mutations have been described in T-ALL
[19]. However, in a recent article JAK3 gain-of-function
mutations were described in T-ALL by Elliott et al. [20]. In our
study, we have identified 3 non-synonymous coding mutations in 2
patients for JAK2 (patient TLE37 had two mutations) and 4 non-
synonymous coding mutations in 1 patient and 2 cell lines (SUPT1
cell line had two mutations) for JAK3. (Table S3). Sanger
sequencing confirmed one JAK2 and all JAK3 variations (Table
S5, Figure 3.A-B). Complementary Sanger sequencing of all
exons of the JAK2 and JAK3 genes in 31 additional T-ALL
patients identified 1 additional JAK2 variant and 2 additional
JAK3 variants (Table S5, Figure 3.A-B). So, in total, we
identified JAK2 mutations in 2 of 46 (4%) T-ALL samples and in 0
of 18 T-ALL cell lines and JAK3 mutations in 2 of 46 (4%) T-ALL
samples and in 2 of 18 T-ALL cell lines (Table S5, Figure 3.A-
B). For JAK2, both mutations were also present in a correspond-
ing remission sample, whereas all JAK3 patient mutations were
somatically acquired. Interestingly, patient TLE44 showed 2
somatic mutations in JAK3, namely A572T and M511I, which
were detected on the same allele (data not shown). Moreover, the
M511I mutation has been detected before in AML and over-
expression of this mutant transformed IL3 dependent 32D cells
and induced T-ALL in mice [21]. Whereas the A572T mutation
was not described before, JAK3 amino acid A572 was found
mutated into a V (A572V mutation) in T-cell leukemia, T-cell
lymphoma, and AML, and this A572V mutant transformed
cytokine dependent hematopoietic cells and induced leukemia in
mice [21], [22], [23], [24].
Identification of New Oncogenes and Tumor Suppressor
Genes in T-ALL
Searching for novel T-ALL driver genes can be performed by
whole-exome sequencing or other genome-wide approaches.
Nevertheless, the Roche/454 platform combined with sequence
capture could be useful in a candidate gene approach. In our
targeted re-sequencing approach, 39 genes were included that
were not causally linked to cancer, but were selected as candidate
oncogenes or tumor suppressor genes, because of their function
(e.g., tyrosine kinases and tyrosine phosphatases) or because family
members had been implicated in cancer (e.g., TYK2 for the JAK
family, TET1 because TET2 is a known cancer gene). Figure 2.B
indicates the exonic and splice site mutations observed in these
genes and the genes were ranked according to the recurrence of
protein altering variants across patient samples.
Interestingly, 4 of the 15 sequenced patient samples contain a
variation in TET1. The TET gene family (TET1, TET2, TET3)o f
epigenetic regulators is important for the hematology field because
of the observation of TET2 mutations in 10–25% patients with
various myeloid hematologic diseases [25], [26], [27]. To better
assess the mutation frequency of TET1 in T-ALL, we performed
supplemental Sanger sequencing of TET1 in all cell lines and
patient samples and in a panel of 22 additional T-ALL cases.
Overall, this resulted in the identification of TET1 variants in 5/37
(13.5%) of analyzed patients and in 1/18 T-ALL cell lines
(KARPAS-45) (Table S6 and Figure 4). The somatic status of
detected TET1 variants was confirmed for 1 case (H1297Y) where
a remission sample was available. We also investigated the variants
in TET2 and TET3 picked up by 454 and performed additional
Sanger sequencing for these genes. TET2 variants were detected in
2 cell lines (JURKAT and KARPAS45) and one TET3 variant
was detected in the CCRF-CEM cell line, no T-ALL patient
samples (0/46) harbored acquired TET2 or TET3 mutations
(Table S6).
Mutations in tyrosine phosphatase genes, that act as negative
regulators of tyrosine signaling, were identified in many T-ALL
cell lines and also in several T-ALL patients. Additional mutations
in SPRY genes, negative regulators of the RAS/MAPK pathway,
were also detected. We identified a homozygous variation in
SPRY3 in one T-ALL patient sample, and 3 mutations in SPRY4 (2
mutations in cell lines and 1 somatically acquired mutation in a T-
ALL patient sample). Sanger sequencing confirmed the presence
of these mutations, but did not reveal any additional mutations of
SPRY3/SPRY4 in 22 additional T-ALL cases, bringing the
SPRY4 mutation frequency to 1/37 T-ALL patients and 2/18 T-
ALL cell lines (Table S7, Figure 5).
Finally, we also identified several mutations in tyrosine kinases
(IGF1R, TYK2, TNK1, and MST1R) and associated signaling
proteins (IRS2, SOCS3), but the majority of these mutations were
found in cell lines, while primary patient samples showed a much
lower frequency of these mutations. The most frequently mutated
gene across all cell lines and patient samples was the insulin
receptor substrate 2 (IRS2) gene, showing non-synonymous coding
mutations in 6 cell lines and in one patient sample. Also frequently
mutated was TYK2, with mutations observed in 6 cell lines; one
stop-gain variant and 5 non-synonymous coding variants.
Although none of the 15 patient samples carried a mutation in
TYK2, it could be present at low frequency in patients. To test
this, we performed complementary sequencing of TYK2 in 93 T-
ALL, 54 AML and 53 B-ALL patient samples. Despite the high
frequency of TYK2 variations in T-ALL cell lines, TYK2 variants
were detected only in 2 of 93 T-ALL and 1 of 54 AML cases
(Table S5, Figure 3.C-D).
Evidence for the Accumulation of Specific Mutations
During in vitro Culture of the T-ALL Cell Lines
The mutation frequency of TYK2 in T-ALL cell lines
compared to primary T-ALL samples was substantially different,
with a high mutation rate of TYK2 in cell lines, but only a low
mutation rate in primary samples. To determine if this could be
due to the accumulation of TYK2 mutations during culturing of
the cells, we sequenced TYK2 in different clones of the same T-
ALL cell line (Table 1). For the CCRF-CEM cell line, we
obtained 5 different subclones that were collected over the years.
Interestingly, whereas the R1027H variant was present in all
analyzed samples, the A35V variant was only present in our line
and in one additional CCRF-CEM clone. In the KARPAS-45 cell
line, the Q830* variation was present in 3 different clones. In
contrast, only our JURKAT line contained the C192Y mutation,
while this was absent in 2 other clones available at DSMZ (www.
dsmz.de) (Table 1). These data suggest that at least some TYK2
Figure 2. Mutations in the 97 genes. Coding mutations in known cancer genes (A) and candidate genes (B) are indicated with different color
codes. Panel A is further subdivided into (I) genes that are known to be drivers in T-ALL, and (II) the genes that have recurrent somatic mutations in
various human cancers. The cell lines are located to the left of the table, and the patient samples are located to the right. Genes are ranked according
to the frequency of protein altering mutations in the patient samples.
doi:10.1371/journal.pone.0038463.g002
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and thus are unlikely to represent an oncogenic event important
for the development of leukemia in vivo. In addition, analysis of the
transforming properties of these mutants in Ba/F3 cells could not
identify major differences between wild type TYK2 and variants of
TYK2 detected in cell lines or patient samples and we could not
show any autophosphorylation of TYK2 in T-ALL cell lines
containing TYK2 variants (data not shown).
These data confirm important differences between cell lines and
primary patient samples, which may reflect the accumulation of
mutations during in vitro cell culture.
Discussion
We demonstrated that the targeted sequencing approach with
an optimized analysis setting can be used to identify oncogenic
mutations. This approach could be of particular interest for the
detection of point mutations in a set of important oncogenes and
tumor suppressors or other disease related genes for diagnosis,
prognosis prediction or therapy choice. Such information could be
generated in a relatively short timeframe and with unprecedented
detail. One of the major advantages over classical Sanger
sequencing is the higher throughput of this method allowing that
all exons of a gene set of this size can easily be sequenced. As such,
full information is provided and rare variants or even previously
undiscovered mutations in a particular gene can be detected.
Indeed, of the 160 exonic and splice site variants (excluding the 61
synonymous variations) detected in the cell lines and patient
samples across our panel of cancer genes, only 40 are found in the
COSMIC database [16], of which 24 are associated specifically
with T-ALL. Although for some genes mutation hotspots exist
(e.g., the KRAS G12, G13, Q61 mutations), the function of most
cancer genes can be affected by mutations at different positions.
Therefore, for most cancer genes the entire coding sequence needs
to be re-sequenced, and for this the Roche/454 technology is
particularly suitable.
To detect mutations using next-generation sequencing - either
to replace or complement molecular diagnosis - standardized
bioinformatics analysis pipelines with very high accuracy are
Figure 3. JAK kinase mutations. (A) Sanger sequencing chromatograms corresponding to confirmed JAK2/JAK3 variants. (B) Domain structure of
JAK2 and JAK3 proteins with indication of novel detected variants. Non-somatic variants are indicated with an asterisk. (C) Sanger sequences showing
examples of TYK2 variants detect in T-ALL cell lines or in leukemia patient samples. (D) Schematic representation of TYK2 protein structure with
indication of all novel TYK2 variants detected in this study. Non-somatic variants are indicated with an asterisk.
doi:10.1371/journal.pone.0038463.g003
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the sequence reads to the reference genome, a variation calling
algorithm to identify differences between the sample and the
reference, and a variation filtering algorithm.
We compared multiple combinations of mapping and variation
calling algorithms, and found that combining two mappers,
namely SSAHA-2 and BWA-SW, followed by Atlas-SNP2 yields
the most accurate variation detection results. Adding two mapping
algorithms filters out false positive variant predictions due to
erronous mapping, and the error model of Atlas-SNP2 enables the
elimination of reads that have multiple best matches in the
reference genome. We also found that additional data filters on
depth of coverage and on variant allele frequency further
increased both the sensitivity and specifity of variation detection.
We encountered several technical limitations during data
analysis. First, we had to remove duplicate reads introduced by
PCR amplification steps during sample preparation since we
noticed these were causing false positive SNV predicitons. Second,
we could only predict SNVs, while indels (small insertions and
deletions) had to be ignored since our work (data not shown) and
previous studies indicate that 454 reads are not suited for indel
detection due to the large amount of false positive results [4]. In a
diagnostic setting, where 100% specificity is pursued, it is critical to
identify genes or regions in genes that are prone to acquisition of
Figure 4. TET1 mutations in T-ALL. (A) Sanger sequencing chromatograms representing confimed TET1 variants. (B) Schematic representation of
TET1 protein structure with indication of all novel TET1 variants detected in this study. Variants detected in cell lines are depicted above the TET1
protein, variants detected in leukemia patient samples are below the TET1 protein. Non-somatic variants are indicated with an asterisk.
doi:10.1371/journal.pone.0038463.g004
Figure 5. SPRY4 mutations. (A) Sanger sequencing chromatograms showing confirmed SPRY4 variants. (B) Domain structure of the SPRY4 protein
with indication of novel detected variants.
doi:10.1371/journal.pone.0038463.g005
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Likewise, genomic rearrangements are important causes of T-
ALL but require complementary detection technologies.
We believe that using a long read sequencing technology, such
as Roche/454 or the more recent Pacific Bioscience, provides
particular advantages with regards to both sensitivity and
specificity of variation detection. First, long read alignment allows
better distinction between highly similar genes in the genome. For
example, one of the genes we re-sequenced was NOTCH1, a gene
with multiple homologs (namely NOTCH2, NOTCH2Nl,
NOTCH3 and NOTCH4). However, we observed no reads
mapping to any of these homologs, even though we mapped the
reads to the entire genome. This indicates that both the sequence
capture and the mapping were specific. On the other hand, we
also encountered an example where the sequence capture was not
specific. Namely, the PMS2 gene is one of the targeted genes in
our study, yet we observed reads mapping to the PMS2
pseudogene, PMS2CL, which contains the first six exons of
PMS2 gene. Thanks to the use of long reads, this causes no
problems for variation detection because for each gene the
respective reads mapped uniquely to the correct gene, either PMS2
or PMS2CL. Note that the capture technology provides additional
cues to achieve higher specificity because not only the exons are
covered in the capture but also the flanking intronic regions.
Therefore, the alignment is ‘aided’ by the intronic regions, where
sequence similarity between homologs is lower, allowing for the
reads to be correctly attributed to their origins in the genome.
Second, mapping long reads to a reference genome is more
robust towards extensive local variation, which can be present in
particular genomic regions, or can be higher when samples are
sequenced from a different ethnicity compared to the reference
genome [28]. We indeed found several regions that contain a high
number of SNPs within a short sequence window. For example,
there are 22 SNP clusters across all samples in a window of 200 bp
with at least 3 SNPs, and 5 distinct clusters in a window of 100 bp
with at least 3 SNPs. Figure S3 shows several examples, such as
cluster of three SNPs within 100 bp in the SUMF1 gene in the
ALLSIL cell line, and a cluster of 4 SNPs in a 200 bp window in
the PTPRM gene in CCRF-CEM cell line. Nevertheless, in both
cases a high coverage is obtained (36x and 46x respectively). These
examples show that long reads enable a correct alignment and
variation discovery, in contrast to short read sequencing technol-
ogies for which the mapping algorithms usually allow for a
maximum of two mismathes per read.
We applied our analysis strategy to T-ALL by sequencing a set
of 97 genes. This set consists of 58 known oncogenes and tumor
suppressors in T-ALL and other cancers, and 39 genes selected via
a candidate approach. Regarding the identification of variations in
these genes using 454 sequencing and our optimal optimized
analysis pipeline, we reached 95% sensitivity and 93% specificity
on a confirmation set of 210 variants validated by capillary
sequencing. Furthermore, we detected 85.7% of the mutations
reported in 11 cell lines that were also sequenced in the Cancer
Cell Line project. High performance of our resequencing
approach is also illustrated by the fact that we identified mutations
in known candidate drivers in T-ALL that were included in the
collection of known cancer genes such as NOTCH1 [29], FBXW7
[30], PTEN [31], PHF6 [14], WT1 [32], [33] and PIK3CA [34].
We detected mutations in several known cancer genes where a
link to T-ALL has not been established yet, such as JAK3.
Interestingly, a recent article confirmed the mutation status of this
gene in the context of T-ALL [20]. We also identified novel
mutations in genes that were not previously associated with T-ALL
tumorigenesis such as TET1, SPRY3 and SPRY4.
It is remarkable that more novel sequence variants are found
per cell line sample than per patient, and that genes were in
general more frequently mutated in cell lines than in patients.
Excessive gene mutations can be explained by potential genomic
instability of cells in culture, or can be caused by in vitro cell culture
conditions. This hypothesis could be confirmed for TYK2, a very
striking example for which 7/18 (38%) T-ALL cell lines contain
novel TYK2 sequence variants as opposed to only 2/93 (2%) T-
ALL patients. Interestingly, we could demonstrate that several
TYK2 variants in cell lines had been acquired during culture. It
remains to be determined what is promoting the frequent
acquisition of TYK2 variants in these T-ALL cell lines as opposed
to T-ALL patients. The most obvious explanation are differences
between the in vitro cell culture conditions and the physiological
environment of T-ALL cells. As several cytokine signaling
pathways depend on TYK2, presence of different cytokines
and/or different concentrations of cytokines that use TYK2
signaling might be critical. These observations underscore once
more that data obtained from cell culture models should be
interpreted with care, especially when extrapolating these data to
patient samples.
It is nevertheless interesting to note that this tendency of higher
mutation frequency in cell lines compared to patient samples does
Table 1. Analysis of TYK2 variants in cell lines over time and
in different subclones.
Cell line Tested variant Result
CCRF-CEM Cools lab R1027H present
CCRF-CEM 2011 DSMZ (ACC240) R1027H present
CCRF-CEM subclone 1 DSMZ R1027H present
CCRF-CEM subclone 2 DSMZ R1027H present
CCRF-CEM subclone 3 DSMZ R1027H present
CCRF-CEM subclone 4 DSMZ R1027H present
CCRF-CEM subclone 5 DSMZ R1027H present
CCRF-CEM Cools lab A35V present
CCRF-CEM 2011 DSMZ (ACC 240) A35V present
CCRF-CEM subclone 1 DSMZ A35V absent
CCRF-CEM subclone 2 DSMZ A35V absent
CCRF-CEM subclone 3 DSMZ A35V absent
CCRF-CEM subclone 4 DSMZ A35V absent
CCRF-CEM subclone 5 DSMZ A35V absent
KARPAS-45 Cools lab Q830* present*
KARPAS-45 2011 DSMZ (ACC105) Q830* present*
KARPAS-45 1994 DSMZ (ACC105) Q830* present*
JURKAT Cools lab C192Y present
JURKAT 2011 DSMZ (ACC 282) C192Y absent
JURKAT 1992 DSMZ (ACC 282) C192Y absent
Presence of the TYK2 R1027 and A35V variants was tested in the CCRF-CEM cell
line from our group (‘‘CCRF-CEM Cools lab’’) as well as in the CCRF-CEM cell line
as it is currently sold by DSMZ (‘‘CCRF-CEM 2011 DSMZ (ACC240)) and in 5
different CCRF-CEM subclones that DSMZ collected over the years. Similarly,
KARPAS-45 from the Cools lab and the KARPAS-45 lines obtained from DSMZ in
2011 and in 1994 were screened for presence of the TYK2 Q830* variant.
JURKAT cells from the Cools lab as well as JURKAT provided by DSMZ in 2011
and 1992 were tested for the TYK2 C192Y variant.
*This cell line has 4 copies of chromosome 19 containing TYK2. The height of
the variant peak on the chromatogram suggests that only 1 copy of TYK2
contains the Q830* variant.
doi:10.1371/journal.pone.0038463.t001
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TET1, showing novel variants in only 1/18 cell lines (KARPAS-
45) versus 5/37 (13.5%) patients.
In conclusion, we describe a method for fast re-sequencing of a
moderate size gene set of 97 genes using 454 next generation
sequencing equipment that would be suitable for implementation
into the clinic. Our results show that this setting is useful to identify
(i) known mutations in known driver genes; (ii) new mutations in
known drivers; and (iii) oncogenes or tumor suppressors that had
not previously been associated with a specific subtype of cancer
based on a candidate gene approach.
The optimized data analysis pipeline, which was assembled
from publicly available tools, slightly exceeded the performance of
the Roche gsMapper software with 95% sensitivity and 93%
specificity for SNV detection, and subsequent analysis of the
Roche/454 data from the T-ALL cell lines and patient samples
confirmed previously known oncogenes and tumor suppressors in
T-ALL and identified previously unrecognized rare somatic
mutations in TET1 and SPRY4 in T-ALL patients. Screening a
larger patient series should reveal the exact mutation frequency of
these genes in T-ALL and whether mutations in these tumor
suppressors also play a role in other types of hematopoietic
malignancies.
Materials and Methods
Targeted Genes
97 genes were selected for sequencing in this study. The gene set
consists of genes that are known to be involved in oncogenesis of
T-ALL (and other cancer types), and a large set of kinases and
phosphotases due to their potential therapeutic value. In total, 56
of the selected genes have been causally implicated in cancer
according to Census [2] (extracted on 10th of November 2011)
and 81 have somatic mutations in cancer according to COSMIC
[16] (v48 release). According to the Molecular Signature Database
[35] extracted on 10th of September 2010) there are 40 tumor
suppressors and 32 oncogenes among the targeted 97 genes.
Twenty of the 24 known cancer genes from the NCI-60 cell line
set [36] are also included in the selected genes. Functional
classification of the genes performed with DAVID [37] shows
enrichment for GO terms related to cell proliferation and to
signaling cascades, besides the expected enrichment for kinase and
phosphotase activity (Figure S4; Table S8).
Cell Lines and Patient Samples
All T-ALL cell lines originated from DSMZ (Braunschweig,
Germany). Samples from patients with T-ALL (n=93), Acute
myeloid leukemia (AML) (n=54) and B-cell acute lymphoblastic
leukemia (B-ALL) (n=53), obtained at diagnosis and remission
samples from T-ALL patients (n=42) were collected at the
University Hospital Leuven and VU Medical Center Amsterdam.
Diagnosis of T-ALL, AML or B-ALL was based on morphology,
cytogenetics and immunophenotyping according to the World
Health Organization and European Group for the Immunological
Characterization of Leukemias (EGIL) criteria. Informed consent
was obtained from all subjects and experiments were approved by
the ethical committee of the University Hospital Leuven.
Sequence Capture and Pyrosequencing
Preparation of a shot-gun DNA sequencing library and capture
of the exons, with flanking intron junctions of 97 genes (Table S9)
was performed on custom designed Nimblegen sequence capture
385K Version 2.0 Arrays (Roche Applied Science, Mannheim,
Germany) according to the manufacturer’s instructions. The
content of these arrays is described in (Table S9). Captured DNA
was pyrosequenced on a GS FLX instrument (Roche).
Evaluation of the Alignment and Variant Calling
Algorithms
The performance of the alignment and variant calling
algorithms was evaluated to determine the optimal method for
analyzing 454 reads. Eight analysis pipelines were constructed
from long read aligners BWA-SW [1], SSAHA2 [7], BLAT [8]-
ERROR; and variant callers SAMTools [9], VarScan [10], Atlas-
SNP2 [11]. (We will use the term ‘pipeline’ to refer to a
combination of an aligner and a variant caller in the remaining
part of this manuscript.) In addition to these pipelines, gsMapper
was also included in the evaluation. The aligners map the
sequence reads to the human reference sequence (NCBI Build
36.1). To remove duplicate reads in the data, the alignments
generated by SSAHA2 and BWA-SW were processed further
using Picard [38] (BLAT alignments were not ‘‘dedupped’’ since
Picard requires the alignments in BAM format, and format
conversion was not possible). Reads mapping to multiple locations
in the reference genome (possibly coming from the homologes
and/or pseudogenes of the genes targeted in the capture) are
marked with a mapping quality of 0.
The pipelines were implemented and reviewed on 7 cell lines:
P12ichikawa, KE-37, ALL-SIL, CCRF-CEM, KARPAS45, SUPT1,
DND41.
Initial SNV predictions were performed with following settings:
N SAMTools: with pileup -c command, with total coverage
threshold of 3 and SNP quality threshold of 20
N VarScan: with pileup2snp –min_coverage 3–min_reads2 2
min_avg_qual 15–min_var_freq 0.01–p_value 0.99
N Atlas-SNP2: with total coverage threshold of 3
N gsMapper: with HCDiff (high confidence differences) strategy;
requiring the following criteria:
1) There must be at least 3 reads with the difference.
2) There must be both forward and reverse reads showing
the difference, unless there are at least 5 reads with
quality scores over 20 (or 30 if the difference involves a
5-mer or higher).
3) If the difference is a single-base overcall or undercall,
then the reads with the differences must form the
consensus of the sequenced reads.
The SNPs to be confirmed with capillary sequencing were
selected from the predictions generated with these settings.
Then, predictions from the pipelines were filtered with varying
VAF and DoC thresholds. Two VAF thresholds (0.20 and 0.30)
and two DoC thresholds (3 and 10) were used. SAMTools
pipelines were also processed with samtools varFilter command,
which implements minimum RMS mapping quality of 25,
minimum read depth of 3, maximum read depth of 100, SNP
within 10 bp around a gap to be filtered, and maximum number
of SNPs in a window of 10 bp to be 2. Atlas-SNP2 pipelines were
also filtered with posterior SNP-probability threshold
P(SNP|Sj,cj).
The performance of each pipeline was evaluated by Sanger
resequencing of 210 variants that were sampled from the pooled
set of all predicted variants from all pipelines (Table S10) and the
performance of each pipeline was quantified by calculating
sensitivity, specificity and Matthews correlation coefficient
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Sanger Sequencing
Whole genome amplified DNA (REPLI-g system, Qiagen,
Hildenberg, Germany) from primary leukemia or remission
samples was used as template for PCR amplification of indicated
genes. PCR products were Sanger sequenced and inspected for the
presence of sequence variants using Mutation Surveyer software
(Softgenetics, State College, PA) and CLC DNA Workbench 6
(CLC Bio, Aarhus, Denmark). All variants that were detected in
whole genome amplified material were subsequently validated in
non-amplified original patient material. Primer sequences are
available upon request.
Data Availability
Sequence data has been deposited at the European Genome-
phenome Archive (EGA, http://www.ebi.ac.uk/ega/), which is
hosted by the EBI, under accession number EGAS00001000268.
Supporting Information
Figure S1 Mis-alignment in SSAHA2 causes a false
prediction in TET2. IGV (Integrative Genomic Viewer)
software visualizes alignment of next generation sequencing reads
to the reference sequence.15 In IGV, each sequence read is
represented as a grey rectangle and the reference sequence is
represented at the bottom. If there is base in a read that is different
from the reference sequence, it is indicated with the corresponding
letter. This figure shows the IGV output when anlayzing the same
set of reads with the BWA-SW (top) and with the SSAHA2
(bottom) algorithms for sequence alignment. Looking at the
alignments generated by these two algorithms revealed that
SSAHA2 alignment was incorrectly positioning 3 reads (as
indicated by colored read names on the plot), causing a false
variant call on chr4:106384366 and resulting false prediction of a
non-synonymous coding mutation in the TET2 gene.
(PDF)
Figure S2 Low coverage exons have significantly higher
GC-content. Comparing the GC-content of the exons with low
and high coverage revealed that the two groups have significantly
different GC-content (p-value 2.2e-16), with low coverage exons
having higher GC-content.
(PDF)
Figure S3 SNP clusters identified in (A) SUMF1 gene in
ALLSIL cell line and (B) PTPRM gene in CCRF-CEM cell
line.
(PDF)
Figure S4 Functional classification of the 97 selected
genes based on molecular function terms.
(PDF)
Table S1 Performance comparison of different analysis
pipelines and parameter settings.
(XLSX)
Table S2 Performance of the pipelines under varying
parameters.
(XLSX)
Table S3 368 retained SNVs.
(XLSX)
Table S4 Point mutations from the Cancer Cell Line
project and their detection status by different analysis
pipelines.
(XLSX)
Table S5 Sanger confirmed variants in JAK genes.
(XLSX)
Table S6 Sanger confirmed variants in TET genes.
(XLSX)
Table S7 Sanger confirmed mutations in SPRY genes.
(XLSX)
Table S8 Top 20 enriched (a) molecular function and (b)
biological process GO terms from 97 genes.
(XLSX)
Table S9 97 selected genes for capture and their
targeted exons.
(XLSX)
Table S10 Selected positions for Sanger sequencing
validation.
(XLS)
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